Cargando…

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma

Autograft absolute lymphocyte count (A-ALC) is a prognostic factor for survival in non-Hodgkin lymphoma (NHL) after autologous stem cell transplantation (ASCT). An A-ALC is dependent upon the preaphaeresis absolute lymphocyte count (PA-ALC) at the time of aphaeresis. It was hypothesised that the tim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holtan, Shernan G, Porrata, Luis F, Inwards, David J, Ansell, Stephen M, Micallef, Ivana N, Johnston, Patrick B, Litzow, Mark R, Gastineau, Dennis A, Markovic, Svetomir N
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2006
Materias:	Haematological Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472657/ https://www.ncbi.nlm.nih.gov/pubmed/16704437 http://dx.doi.org/10.1111/j.1365-2141.2006.06088.x

Ejemplares similares

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
por: Porrata, Luis F., et al.
Publicado: (2010)

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation
por: Porrata, Luis F., et al.
Publicado: (2015)

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation
por: Porrata, Luis F., et al.
Publicado: (2013)

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
por: Sawas, Ahmed, et al.
Publicado: (2017)

Early‐stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long‐term patient outcomes
por: Parsons, Susan K., et al.
Publicado: (2018)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
por: Bröckelmann, Paul J., et al.
Publicado: (2018)

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2014)

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial
por: Pettengell, Ruth, et al.
Publicado: (2016)

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
por: Robak, Tadeusz, et al.
Publicado: (2016)

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
por: Van Dyke, Daniel L., et al.
Publicado: (2016)

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
por: Lin, Yi, et al.
Publicado: (2014)

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
por: Jones, Jeffrey, et al.
Publicado: (2018)

Primary therapy and survival among patients with nodular lymphocyte‐predominant Hodgkin lymphoma: a population‐based analysis in the Netherlands, 1993–2016
por: Posthuma, Hidde L. A., et al.
Publicado: (2019)

Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia
por: Huang, Ying‐Jung, et al.
Publicado: (2019)

Real‐world clinical experience in the Connect(®) chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres
por: Mato, Anthony, et al.
Publicado: (2016)

Long‐term outcome of immunologic autograft engineering
por: Porrata, Luis F., et al.
Publicado: (2022)

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
por: Sharman, Jeff P., et al.
Publicado: (2016)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
por: Veldman, Johanna, et al.
Publicado: (2021)

An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy
por: Sarid, Nadav, et al.
Publicado: (2015)

Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014)

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)

Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)
por: Townsend, William, et al.
Publicado: (2019)

Acute myeloid leukaemia: challenges and real world data from India
por: Philip, Chepsy, et al.
Publicado: (2015)

Systemic Amyloidosis in England: an epidemiological study
por: Pinney, Jennifer H, et al.
Publicado: (2013)

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry
por: Andersen, Maja Dam, et al.
Publicado: (2022)

Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years
por: Wahlin, Björn Engelbrekt, et al.
Publicado: (2021)

Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
por: Xu, Jinglan, et al.
Publicado: (2008)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines
por: Leupin, Nicolas, et al.
Publicado: (2006)

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase
por: Kohlmann, Alexander, et al.
Publicado: (2008)

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_9mq098tnv6uaof2usrffiavquo